Only 5 foreign enterprises won the bid, small and medium-sized pharmaceutical companies eye-catching! The fourth batch of countries to draft the results of the election official Xuan!

Pharmaceutical Network February 4th, february 3rd night, Shanghai Sunshine Pharmaceutical Procurement Network "overtime" as scheduled announced the fourth batch of national centralized procurement of drugs to be selected results.
after a whole day of news flying, anxious and waiting after finally the dust settled.
all 45 generic drugs were purchased, a total of 152 enterprises participated, resulting in 118 pharmaceutical companies to be selected, 158 products to be selected.
the number of selected products alone, the proportion of the fourth batch of state-owned mining enterprises to be selected reached 71%, significantly higher than the first three batches.
4-7 February as the publicity period, four days later to determine the final results of the election.
price competition in the end, the original research is not invincible to lose the main position of this official announcement of the results of the proposed election, the most concerned point is naturally the price.
the highest effective declared price, the average price reduction of 45 drugs this time 52%, of which the highest decline of 96%.
multinational pharmaceutical companies, which had shown increased enthusiasm, lost most of their bids in the fourth batch of state mining, with 21 foreign companies participating in the offer, and only five foreign companies were selected.
is worth noting that the clinical hot varieties of competitive sword lightsaber shadow, and the trend of domestic substitution is becoming more and more obvious.
the two varieties of hydrochloric acid bromoso injection and the injection of sodium Parexib, for example, there are striking similarities: 1. Competition is extremely fierce.
According to the rules of more than 13 competitive enterprises can be selected for up to 10, the two varieties of the national market are divided into 10 supply areas, by 16 enterprises to compete, the final 10 enterprises to be selected; according to
-meter intranet data, in 2019 China's public medical institutions terminal ammonia bromoso injectables sales of 5.98 billion yuan, Grigg Ingeham's original research drug market share accounted for 23.56 percent, ranked first.
same year, Parexib sodium public hospital terminal sales of 1,994 million yuan, Pfizer's original drug market share of more than 60%.
has now been squeezed out of the public list;
10 enterprises with ammonia bromine injections allocated 1 billion purchases in the first year, while Hebei, Hubei, Yunnan, Gansu and other supply areas 2ml:15mg specifications reported a price of 0.23 yuan per branch.
prices, a number of enterprises in the price reduction range of more than 80%, up to 93.3%.
, while the original research price fell by only 0.1%, Parrestib sodium fell by 94.8%, Zhengda Tianqing and more than a dozen domestic pharmaceutical companies, the price decline is also more than 90%.
these are dominant characteristics, behind the hidden trend: from the final release of the proposed selection of varieties, over-evaluation of generic drugs to seize the original drug market has been unstoppable.
E.g. Parexib sodium, the winning enterprise first place for Emeishan Tonghui, floor price as low as a single 2.98 yuan, and the same winning Shandong Luoxin only last month through a consistent evaluation, Hengrui is not included in the winning bid, but its Parexib sodium february 2 just after the evaluation, can think of the next procurement cycle competition intensity.
fact, there are similarities in the competitive landscape of large varieties such as ibuprofen injections, doso-tea-alkali injections, pythola injections, and boratezomi injections.
Head enterprises occupy the C-position outside the hospital market wolf smoke throughout this public list, another intuitive feeling is that some products to bid for many small and medium-sized enterprises, some even unknown appearance in front of the public.
addition, the main character is still a domestic head enterprise. The latest data of
meters intranet show that the fourth batch of national varieties of Yangzijiang Pharmaceuticals has a total of 9 varieties over-evaluation, China Biopharmaceuticals has 8 varieties over-evaluation, Qilu Pharmaceuticals, Stone Pharmaceutical Group, Fosun Pharma each have 7 over-evaluation varieties involved.
results show that Yangzijiang Pharmaceuticals 7 varieties winning the bid, Qilu Pharmaceuticals, Stone Pharmaceutical Group, China Biopharmaceuticals have 6 varieties winning the bid, Fosun winning 5 varieties, Colum Pharmaceuticals, Dongsun Pharmaceuticals each have 4 varieties winning the bid.
, which received nine varieties of tickets, is the focus of the fourth batch.
in the previous three batches of four-wheeled collection in Yangzijiang Pharmaceuticals has 13 varieties of winning the bid.
can say that the collection let Yangzijiang Pharmaceuticals taste the sweetness.
the seven winning varieties, the number of injections of parrexib sodium, dosso-tea-alkali injections and other varieties decreased by more than 90%.
propofol medium/long chain fat milk injection, left oxyfluorosa star just after the evaluation, successfully catch the last bus.
Group's Eso meprazole magnesium intestinal capsule is also just approved to catch up with the collection.
Koren Pharmaceuticals hydrochloric acid bromoso injection, propofol medium/long-chain fat emulsion injection, Ngle net tablets and injection of Parexib sodium 4 varieties were all selected;
as the first batch of national harvest big winners, Huahai Pharmaceuticals' Voliconazole tablets successfully won the bid.
before the market opened on February 4th and the evening of February 3rd, some listed companies have disclosed the winning bid for their pharmaceutical products.
need to be concerned about where the products that would otherwise occupy the core market will go? In 2019, for example, sales of the drug in public medical institutions amounted to 1.67 billion yuan, accounting for 100% of the original market share.
in this round of collection, the original research quotation is no match for Hengrui, Baiao Pharmaceuticals and Garden Pharmaceuticals, directly out.
experts said, "For them, whether or not the winning bid is a matter of life and death, although the winning bid after the profit is small, but not the winning varieties are difficult to survive."
" is mostly out of such logic, schizophrenia treatment drug ammonia bili 3 enterprises to be selected, of which 0.2g product rules selected enterprises including the original research drug company Sanofi, a single tablet eventually fell to 1.55 yuan, a drop of nearly 80%.
the practice of the last round of national renewal has found that the evaluation of generic drugs has a strong alternative to the original drug.
the loss of the share of the original drug research country, will certainly accelerate the layout of the off-site market or off-standard market, channels further differentiation.
To dolositin, for example, this need to take long-term drugs, Lilly as the original research enterprises in the market has been sold for more than ten years, there is a certain amount of customer base, the long tail effect of the product is still, lost the share of national mining, but the space outside the hospital can also dig.
this is also the reason why the retail work of prescription drugs in the out-of-hospital market of many multinational companies has been gradually strengthened in recent years, and it is expected that professional empowerment will be given to the out-of-hospital market, and the competition for channels will be fierce.